Danielle Bucco


Expert Discusses Exciting Advancements in Treating GI Cancers

January 08, 2018

The role of precision medicine has become a significant area of study, specifically with genomics and liquid biopsies. With the introduction of next-generation sequencing and an improvement in the understanding of molecular alterations, treatments for patients have begun to be individualized.

Changing the Sequence of Therapies Can Improve Results in NSCLC

December 26, 2017

The variety of treatment options now available for non-small cell lung cancer (NSCLC) — including checkpoint inhibitors and targeted therapies — presents challenges in choosing the right treatment plan.

Immunotherapy Is Entering the Stage 3 Lung Cancer Landscape

December 22, 2017

Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The sBLA is in light of positive progression-free survival (PFS) results from the phase 3 PACIFIC trial.

Examining Immunotherapy's Role in Colorectal Cancer

November 27, 2017

“The very exciting field of checkpoint inhibitors is still evolving, and we are trying to understand where they fit in the world of CRC therapy,” said McCollum, a hematologist and medical oncologist at Texas Oncology.